Story
Sycamore Partners Nears $9 Billion Deal to Sell Boots Pharmacy Chain, WSJ Reports
Summary
Private equity firm Sycamore Partners is reportedly in advanced talks to sell the U.K.-based Boots pharmacy chain to the Weston family for approximately $9 billion, including debt.
Private equity firm Sycamore Partners is nearing an agreement to sell the U.K. pharmacy chain Boots for approximately $9 billion, including debt, according to a report from The Wall Street Journal. The potential buyer is the Canadian arm of the Weston family, a prominent group with a large food-business empire.
Deal Nears Finalization
Citing people familiar with the matter, the report published Wednesday stated that discussions are in an advanced stage. If negotiations proceed successfully, a transaction could be finalized within the coming weeks.
The deal structure values the Boots enterprise, which includes its extensive retail footprint and international operations, at around $9 billion when accounting for its debt load. The parties involved have not made public comments on the reported negotiations.
Strategic Divestment
This potential sale is a direct result of a strategy implemented after Sycamore Partners acquired Walgreens in a take-private transaction in 2025. That deal was valued at $24 billion, including debt.
AdFollowing the acquisition, Sycamore divided the company into five distinct units to facilitate the divestment of non-core assets. The Boots unit represents the former international operations of Walgreens, which includes:
- Boots locations across the U.K.
- Business operations in Thailand, Mexico, Germany, and China.
Market Context
A sale would mark a significant step in Sycamore's plan to unlock value by breaking up the former Walgreens conglomerate. For the Weston family, acquiring Boots would add a major, established brand in the health and beauty retail sector to their extensive portfolio of consumer-facing businesses.
Read next
More on Stocks
PHC Holdings Stock Surges to 3-Year High on Toho Acquisition Offer
Shares in the Japanese healthcare device maker jumped nearly 13% after the company confirmed it had received a non-binding takeover proposal from pharmaceutical firm Toho Holdings.
Indian Stocks Fall 14% in 2026 as Foreign Investors Exit
India's benchmark Nifty 50 index has declined nearly 14% year-to-date, pressured by significant foreign capital outflows and elevated valuations. Strong domestic buying has provided a floor for the market, but macroeconomic headwinds persist.
Japanese Chip Stocks Rally as Micron's Strong AI Outlook Boosts Sector
Shares of major Japanese semiconductor and electronics firms surged after U.S. chipmaker Micron Technology issued a stronger-than-expected forecast, reinforcing investor optimism about demand driven by artificial intelligence.
Ameriprise Financial Authorizes $5.5 Billion Share Buyback Extension
The wealth management firm announced a new share repurchase program running through September 2028, reinforcing its capital return strategy after a recent earnings beat and a more than 10% gain in its stock price since early June.